GHK-Cu, Matrixyl, PAL-GHK and Snap-8 all appear in dermal research, but they do not all act through the same biological pathway. This article discusses GHK-Cu, Matrixyl and PAL-GHK in relation to collagen and extracellular matrix (ECM) biology. Snap-8 is studied through a different proposed mechanism, one involving signaling at nerve terminals.
Keeping these mechanisms separate matters when comparing the evidence, because findings about fibroblast and matrix activity cannot be assumed to apply to a peptide that targets neurotransmitter-release machinery. The same is true in the other direction. Findings are identified throughout as in vitro, meaning outside a living body, or as animal work. Nothing here should be read as an outcome an individual should expect. These are research compounds.
GHK-Cu is the reference point for the ECM-related peptides discussed here, and a dedicated GHK-Cu article covers it in depth. The treatment here is therefore brief. GHK is a tripeptide the body makes itself, with the full name glycyl-L-histidyl-L-lysine, and its copper-bound form is the complex written GHK-Cu.
The foundational cellular evidence is in vitro. Maquart and colleagues showed that GHK-Cu stimulated collagen synthesis in cultured fibroblasts, a direct link between the peptide and matrix production.[1] Animal work then tested whether this appeared in living tissue. In a rat wound-chamber model, the same research line reported a concentration-dependent increase in connective tissue accumulation, including collagen and glycosaminoglycan content.[2] These are cell-culture and rodent findings.
Matrixyl approaches collagen from a different angle, through a fragment of collagen itself. Its active core is the pentapeptide KTTKS, a short sequence derived from the C-terminal propeptide of type I procollagen. Such collagen-derived signaling fragments are sometimes called matrikines.
Katayama and colleagues reported that KTTKS stimulated the production of ECM components in cultured fibroblasts, including type I and type III collagen and fibronectin.[3] That is the in vitro basis for its use.
The practical problem is that a small, charged peptide penetrates skin poorly. The commercial compound is therefore the palmitoylated derivative, palmitoyl pentapeptide-4, with a fatty-acid chain attached to improve lipophilicity, or fat solubility, and delivery. Lintner and Peschard described this lipidation strategy and the palmitoyl-KTTKS molecule that became Matrixyl.[4] Later in vitro skin-permeation work also found greater stability and skin delivery for palmitoyl-KTTKS than unmodified KTTKS.[5]
The important distinction is that the collagen-stimulating signal comes from the KTTKS portion, while the palmitoyl group is a delivery modification, not a separate mechanism.
PAL-GHK, or palmitoyl tripeptide-1, applies that same palmitoylation logic to the GHK sequence: it is GHK carrying a fatty-acid chain. It appears as one component of blended cosmetic actives such as Matrixyl 3000.
PAL-GHK specifically has very limited primary, PubMed-indexed literature of its own. Its rationale is therefore largely extrapolated from the collagen and ECM findings reported in GHK-Cu research,[1] together with the general palmitoylation-for-delivery strategy shared with Matrixyl.[4][5] It does not rest primarily on peer-reviewed mechanistic studies of the palmitoylated tripeptide itself. Readers should treat claims about PAL-GHK as extrapolated from related GHK-Cu and peptide-delivery research rather than as directly demonstrated for PAL-GHK itself.
Snap-8 acts through a different proposed pathway. Also known as acetyl octapeptide-3, it is designed around a sequence derived from the N-terminal region of SNAP-25. SNAP-25 is a protein involved in neurotransmitter release at nerve terminals, and it forms part of the SNARE complex together with syntaxin and VAMP. That complex drives the fusion of neurotransmitter-containing vesicles with the cell membrane, allowing their contents to be released.
Blanes-Mira and colleagues showed in vitro that short peptides based on the SNAP-25 N-terminus could inhibit SNARE complex assembly and reduce regulated exocytosis, the vesicle-release process underlying neurotransmitter signaling.[6]
Snap-8 is proposed to act through the same general mechanism: by mimicking part of SNAP-25, it may interfere with normal SNARE assembly and reduce exocytosis involved in muscle contraction. This mechanism concerns neurosecretion and is distinct from the fibroblast and extracellular-matrix effects discussed for the other peptides.
Importantly, the Blanes-Mira study examined SNAP-25-mimetic peptides as a class, not Snap-8 specifically. It therefore provides mechanistic support for the concept, but not direct experimental evidence for acetyl octapeptide-3 itself.
The evidence for these peptides varies considerably in both type and strength. Much of the cosmetic-peptide literature combines mechanistic cell studies with formulation and product testing. This article focuses on in vitro and animal studies of biological activity, and includes formulation studies only where they help explain peptide delivery.
Skin penetration is an important limitation for small, charged peptides, and is one reason palmitoylation is commonly used. Improved penetration, however, does not by itself demonstrate biological activity.
The evidence for PAL-GHK is also limited. Much of its proposed activity is inferred from research on GHK-Cu and from what is known about palmitoylated peptides. For Snap-8, studies of SNAP-25-mimetic peptides support the proposed mechanism, but it has not been demonstrated directly for acetyl octapeptide-3 itself. None of these findings can be used to predict human outcomes.
GHK-Cu, Matrixyl and PAL-GHK are studied primarily in relation to fibroblast activity and extracellular matrix production. Even so, the amount of direct evidence differs substantially between them. GHK-Cu has support from both cell-culture and animal models, while Matrixyl is supported by in vitro work on its KTTKS sequence. PAL-GHK has a more limited direct evidence base. It is largely discussed on the basis of the established biology of GHK and the rationale for peptide palmitoylation.
Snap-8 is different in both target and proposed mechanism, with research focusing on inhibition of SNARE-dependent neurosecretion rather than matrix production.
The evidence discussed here describes experimental mechanisms investigated in vitro or in animals. It should not be taken as evidence of an expected effect in an individual. These compounds are discussed for research purposes only.
References
Growth hormone secretagogues (GHS) are molecules studied for their ability to make the pituitary gland release growth hormone (GH). Research so far has found that these molecules can reach the same end point by different routes or pathways. This article compar
NAD+, SS-31 and AICAR are all studied in relation to cellular energy metabolism and mitochondrial function, but they work in different ways. NAD+ is an essential coenzyme that several classes of enzyme depend on. SS-31 is a mitochondria-targeted peptide that a
The IGF-1 family includes several research compounds. Each one acts within the insulin-like growth factor 1 (IGF-1) signaling system, or is derived from it. Growth hormone secretagogues work upstream at the pituitary to raise growth hormone, but these compound
The myostatin pathway is one of the clearest biological systems involved in limiting skeletal muscle growth. GDF-8, Follistatin and ACE-031 each act at a different point in this pathway: GDF-8 provides the inhibitory signal, and Follistatin binds and neutraliz
Vesilute is a trade name for the dipeptide Glu-Asp. The one indexed animal study found no difference from its amino acids on the three endpoints it measured.
Thymulin is a zinc-dependent thymic nonapeptide. Its human trials date from the 1980s, it is approved nowhere, and its newest evidence is preclinical.
